undamentalytics Newsletter
Sign in

Maxcyte, Inc. (MXCT) stock

Add to watchlist

Add holding +

NASDAQ: MXCT Nasdaq Life Sciences Tools & Services Next results ~November 10, 2026

C Fundamentals grade

Maxcyte, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.6

Valuation models combined (3)

Base case. Range ~$0.4–$1.0. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Maxcyte, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds78 adding, 61 cuttingOf 28 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Maxcyte files

Where Maxcyte stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $31m, down 13.2% on a year earlier, a smaller fall than the 14.3% decline a quarter earlier. That puts it 43 of 46 for growth among the life sciences tools & services companies we cover. Free-cash-flow margin rose to -76.1% from -107.0% a year earlier. Operating margin widened to -134.6% from -149.6%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $0.40 a share, against a share price of $1.75.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Maxcyte, Inc.'s trailing-twelve-month revenue fell 13.2% year on year, with a free-cash-flow margin of -76.1%. Where it stands out: gross margin of 79.2% ranks 2 of 45 life sciences tools & services companies we cover. Where it lags: revenue growth of -13.2% ranks 50 of 54 life sciences tools & services companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 38.2% while net income grew 20.4%: a 18pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 15.0 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 13.2% over the last 12 months.
  • Loss-making. Operating margin is -134.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -76.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 16.0% of revenue, against a median of 4.4% for life sciences tools & services companies we cover: a real cost that cash-flow figures leave out.
  • Volatile shares. Over the past year the shares showed annualised volatility of 73% and a beta of 1.6 against the S&P 500.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.08 against an average estimate of -$0.09: beat by 14.3%
Revenue
$7m, down 14.5% on a year earlier
Share reaction
+34.9% in the first session after the results on October 14, 2026, against -0.8% for the S&P 500
Guidance given
full year revenue $34m (full year 2026); core business revenue $28m (full year 2026)
Next report
November 10, 2026; average EPS estimate -$0.08

Maxcyte's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-8.8%
  • 1 week-4.0%
  • 1 month+35.5%
  • This year-6.5%
  • 1 year-5.8%
  • 5 years-86.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$31.1M
Operating margin
-134.6%
Net margin
-114.8%
EPS (TTM, diluted)
$-0.33

Growth

Revenue growth
−13.2%
Change in growth rate
+1.1 pts
Share count change
+1.0%

Cash

Free cash flow (TTM)
-$23.6M
FCF margin
-76.1%
Stock pay % of revenue
16.0%

Earnings

Last results
October 14, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Maxcyte, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Maxcyte, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.95 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.6 ~$0.5–$0.6 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.0 ~$0.8–$2.5 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$0.4 ~$0.4–$0.4 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.6 ~$0.4–$1.0 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Maxcyte, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$10.19$5.46$4.70$4.16$1.55$1.45
Market value$923m$555m$485m$436m$165m$155m
+ Net debt (− = net cash)−$48m−$11m−$47m−$28m−$20m−$15m
Enterprise value$876m$544m$439m$408m$145m$140m
Multiples
Price / sales 27.2x12.5x11.8x11.3x5.0x5.0x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

30 /100

Weak moat

How hard Maxcyte's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -6.9% of total assets over 5 years.

  • Pricing power 18 / 20

    Gross margin has been a median 87.7%, moving by 4.3 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -101.0%; its worst year was -149.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -66.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (35 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, after the close. Analysts expect revenue of $7m and EPS of −$0.08 (range −$0.09 to −$0.08) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.28 +23% $32m −3%
Next −$0.25 +11% $37m +16%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.6% on 90 days ago. In the last 30 days, 1 analyst raised Maxcyte, Inc.'s forecast and 3 cut it.

Consensus EPS forecast Maxcyte, Inc., last 90 days
−$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.28 Current fiscal year, 60 days ago: −$0.27 Current fiscal year, 30 days ago: −$0.28 Current fiscal year, 7 days ago: −$0.28 Current fiscal year, Now: −$0.28 −$0.28 Next fiscal year, 90 days ago: −$0.23 Next fiscal year, 60 days ago: −$0.24 Next fiscal year, 30 days ago: −$0.25 Next fiscal year, 7 days ago: −$0.25 Next fiscal year, Now: −$0.25 −$0.25

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.28−$0.23
60 days ago −$0.27−$0.24
30 days ago −$0.28−$0.25
7 days ago −$0.28−$0.25
Now −$0.28−$0.25

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.09 −$0.08 +14.3%
Dec 2025 −$0.08 −$0.06 +32.1%
Sept 2025 −$0.10 −$0.09 +12.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 14, 2026
  • Full year revenue full year 2026 about $34m Raised
    “Full year revenue expected to be approximately $34 million, compared to prior guidance of $30 million to $32 million, consisting of:” source
  • Core business revenue full year 2026 about $28m Raised
    “Core business revenue of approximately $28 million, compared to prior guidance of $25 million to $27 million.” source
  • SPL Program-related revenue · Strategic Platform License (SPL) Program full year 2026 about $6m Raised
    “SPL Program-related revenue of approximately $6 million for the year, compared to prior guidance of approximately $5 million; SPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and approximately $2 million from commercial royalties.” source
  • SPL milestone payment revenue · Strategic Platform License (SPL) Program - milestone payments full year 2026 about $4m
    “SPL Program-related revenue of approximately $6 million for the year, compared to prior guidance of approximately $5 million; SPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and approximately $2 million from commercial royalties.” source
  • SPL commercial royalties revenue · Strategic Platform License (SPL) Program - commercial royalties full year 2026 about $2m
    “SPL Program-related revenue of approximately $6 million for the year, compared to prior guidance of approximately $5 million; SPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and approximately $2 million from commercial royalties.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

6 analysts, Oct 2026
Buy583%
Hold117%
Sell00%

Monthly trend

  1. Oct 2026516
  2. Sep 2026516
  3. Aug 2026516

Counts of recommendations published by analysts covering Maxcyte, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.8%
of tradable shares
Days to cover
1.81
at average volume
Short interest, 1 month
+57%
to October 15, 2026
Held by institutions
65%
of shares
Held by insiders
1.8%
of shares
Employees
91
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −5.8%

$1.54 on October 31, 2025 to $1.45

ThenNowEffect
Revenue (last 12 months) $36m $31m −13.2%
P/S multiple 4.6x 5.0x +9.5%
Share count 106m 107m −0.9%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years −57.6%

$3.42 on November 3, 2023 to $1.45

ThenNowEffect
Revenue (last 12 months) $41m $31m −23.7%
P/S multiple 8.6x 5.0x −42.1%
Share count 102m 107m −4.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
MXCT−46%−14%−12%−63%−7%
Industry peers (median)−53%−3%−15%−2%+16%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
MXCT50%42%33%33%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
MXCT−67%−56%−40%−75%−56%
S&P 500−25%−10%−8%−19%−9%

Worst fall since July 30, 2021: 96% from September 3, 2021 to March 30, 2026. Getting back needed a 2444% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.68 – $1.76
From 52-week high
−17.6%
vs 50-day average
+15.3%
vs 200-day average
+36.3%
Volatility (1 year)
73%
Beta vs S&P 500
1.58

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±13.5%
After a week
5 up, 7 down
typical move ±17.2%
After a month
2 up, 9 down
typical move ±18.4%
Results releasedNext dayS&P 500 next day5 days21 days
October 14, 2026 +34.9% −0.8% +52.5% —
August 12, 2026 +12.1% +0.9% +12.1% −6.5%
May 12, 2026 +24.8% +0.4% +27.3% +34.6%
March 24, 2026 −8.9% +0.2% −7.1% +13.9%
January 12, 2026 −8.4% 0.0% −15.4% −49.0%
November 12, 2025 −2.6% −1.6% +9.7% −1.9%
November 5, 2025 −8.7% −0.7% −1.9% −8.7%
August 6, 2025 −30.6% +0.7% −33.0% −31.6%
May 7, 2025 −8.6% +1.1% −17.3% −19.2%
March 11, 2025 −7.0% −0.3% −6.7% −26.0%
January 13, 2025 +5.5% +0.3% +15.9% −4.5%
November 6, 2024 −10.4% +3.3% −8.0% −6.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Maxcyte, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Maxcyte, Inc.
$30M $35M $40M $45M $50M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $38M Revenue (TTM), FY23 Q4: $41.3M Revenue (TTM), FY24 Q1: $44.1M Revenue (TTM), FY24 Q2: $45.4M Revenue (TTM), FY24 Q3: $45.6M Revenue (TTM), FY24 Q4: $38.6M Revenue (TTM), FY25 Q1: $37.7M Revenue (TTM), FY25 Q2: $35.8M Revenue (TTM), FY25 Q3: $34.4M Revenue (TTM), FY25 Q4: $33M Revenue (TTM), FY26 Q1: $32.3M Revenue (TTM), FY26 Q2: $31.1M $31.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $38M
FY23 Q4 $41.3M
FY24 Q1 $44.1M
FY24 Q2 $45.4M
FY24 Q3 $45.6M
FY24 Q4 $38.6M
FY25 Q1 $37.7M
FY25 Q2 $35.8M
FY25 Q3 $34.4M
FY25 Q4 $33M
FY26 Q1 $32.3M
FY26 Q2 $31.1M
Revenue growth, TTM YoY Maxcyte, Inc.
-40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -9.4% Revenue growth, TTM YoY, FY23 Q4: -6.7% Revenue growth, TTM YoY, FY24 Q1: 6.8% Revenue growth, TTM YoY, FY24 Q2: 11.7% Revenue growth, TTM YoY, FY24 Q3: 19.9% Revenue growth, TTM YoY, FY24 Q4: -6.4% Revenue growth, TTM YoY, FY25 Q1: -14.5% Revenue growth, TTM YoY, FY25 Q2: -21.3% Revenue growth, TTM YoY, FY25 Q3: -24.5% Revenue growth, TTM YoY, FY25 Q4: -14.5% Revenue growth, TTM YoY, FY26 Q1: -14.3% Revenue growth, TTM YoY, FY26 Q2: -13.2% -13.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -9.4%
FY23 Q4 -6.7%
FY24 Q1 6.8%
FY24 Q2 11.7%
FY24 Q3 19.9%
FY24 Q4 -6.4%
FY25 Q1 -14.5%
FY25 Q2 -21.3%
FY25 Q3 -24.5%
FY25 Q4 -14.5%
FY26 Q1 -14.3%
FY26 Q2 -13.2%
Operating margin (TTM) Maxcyte, Inc.
-200% -150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -123.4% Operating margin (TTM), FY23 Q4: -117.0% Operating margin (TTM), FY24 Q1: -107.6% Operating margin (TTM), FY24 Q2: -101.9% Operating margin (TTM), FY24 Q3: -101.7% Operating margin (TTM), FY24 Q4: -132.5% Operating margin (TTM), FY25 Q1: -135.9% Operating margin (TTM), FY25 Q2: -149.6% Operating margin (TTM), FY25 Q3: -155.6% Operating margin (TTM), FY25 Q4: -157.1% Operating margin (TTM), FY26 Q1: -141.8% Operating margin (TTM), FY26 Q2: -134.6% -134.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -123.4%
FY23 Q4 -117.0%
FY24 Q1 -107.6%
FY24 Q2 -101.9%
FY24 Q3 -101.7%
FY24 Q4 -132.5%
FY25 Q1 -135.9%
FY25 Q2 -149.6%
FY25 Q3 -155.6%
FY25 Q4 -157.1%
FY26 Q1 -141.8%
FY26 Q2 -134.6%
FCF margin (TTM) Maxcyte, Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -88.7% FCF margin (TTM), FY23 Q4: -61.5% FCF margin (TTM), FY24 Q1: -70.1% FCF margin (TTM), FY24 Q2: -55.9% FCF margin (TTM), FY24 Q3: -46.6% FCF margin (TTM), FY24 Q4: -75.8% FCF margin (TTM), FY25 Q1: -87.5% FCF margin (TTM), FY25 Q2: -107.0% FCF margin (TTM), FY25 Q3: -119.8% FCF margin (TTM), FY25 Q4: -109.5% FCF margin (TTM), FY26 Q1: -90.9% FCF margin (TTM), FY26 Q2: -76.1% -76.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -88.7%
FY23 Q4 -61.5%
FY24 Q1 -70.1%
FY24 Q2 -55.9%
FY24 Q3 -46.6%
FY24 Q4 -75.8%
FY25 Q1 -87.5%
FY25 Q2 -107.0%
FY25 Q3 -119.8%
FY25 Q4 -109.5%
FY26 Q1 -90.9%
FY26 Q2 -76.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 22 26 34 44 41 39 33 31
Gross profit 19 23 30 39 37 32 27 25
EBITDA −12 −10 −17 −25 −44 −47 −48 −38
Operating income −12 −11 −18 −27 −48 −51 −52 −42
Net income −13 −12 −19 −24 −38 −41 −45 −36
Diluted EPS −$0.23 −$0.17 −$0.21 −$0.23 −$0.37 −$0.39 −$0.42 −$0.33
Growth (year on year)
Revenue — +21.0% +29.5% +30.6% −6.7% −6.4% −14.5% −13.2%
Margins
Gross margin 88.4% 89.4% 89.2% 88.5% 88.5% 81.6% 81.2% 79.2%
EBITDA margin −54.6% −38.2% −49.5% −55.7% −106.9% −121.4% −144.0% −121.3%
Operating margin −57.4% −42.3% −53.7% −61.8% −117.0% −132.5% −157.1% −134.6%
Net margin −59.6% −45.2% −56.3% −53.3% −91.8% −106.3% −135.1% −114.8%
Free-cash-flow margin −46.6% −41.5% −42.8% −75.1% −61.5% −75.8% −109.5% −76.1%
Cash flow
Cash from operations −9 −9 −11 −15 −22 −28 −34 −23
Capital spending 1 2 4 18 4 2 2 1
Free cash flow −10 −11 −15 −33 −25 −29 −36 −24
Stock-based pay 2 2 8 12 14 13 9 5
Free cash flow after stock pay −12 −13 −22 −45 −39 −42 −45 −29
Balance sheet
Cash 15 19 48 11 47 28 20 15
Total debt 0 5 — 0 0 0 0 0
Net debt (negative = net cash) −15 −14 −48 −11 −47 −28 −20 −15
Diluted shares 56m 69m 91m 102m 103m 105m 106m 107m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $185m
Short-term assets $121mLonger-term assets $63m
What it owes, and who funded it · $185m
Short-term liabilities $10mLonger-term liabilities $16mShareholders' equity $159m
  • Short-term assets cover short-term liabilities $121m of assets due within a year against $10m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $121m short-term assets against $16m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Maxcyte, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.0%
year over year
R&D spending
54.0%
of revenue
Days sales outstanding
46 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated MXCT BNGO RPID OABI TKNO CSBR Median
Revenue, last 12 months $31m $30m $35m $40m $44m $61m $229m
Revenue growth, last 12 months −13.2% 10.0% 16.1% 90.6% 12.3% 6.7% 6.9%
Revenue growth, 3-year average −8.6% −1.4% 22.5% −14.7% 3.7% 4.8% 2.9%
Revenue growth, latest quarter −14.5% 21.4% 10.9% 78.3% 18.5% 8.8% 8.5%
Gross margin 79.2% 47.5% — — 34.6% 49.8% 51.9%
Operating margin −134.6% −106.7% −141.5% −115.9% −36.2% −1.7% −14.3%
Operating margin, 3-year average −128.7% −293.0% −171.1% −278.2% −61.6% −1.2% −22.4%
Net margin −114.8% −106.6% −145.6% −108.1% −38.4% −1.8% −16.1%
Cash from operations / revenue −74.0% −67.9% −113.9% 6.6% −14.4% −9.2% 1.3%
Free-cash-flow margin −76.1% −67.9% −114.8% 5.9% −16.8% −10.1% −2.2%
Free-cash-flow margin, 3-year average −79.7% −150.1% −143.5% −130.3% −32.0% −0.4% 0.6%
Stock pay / revenue 16.0% 11.6% 12.3% 32.7% 6.7% 3.0% 4.4%
Change in share count 1.0% — 4.4% 19.2% 1.0% −2.4% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth -13.2% 6.9% 50 of 54
Change in growth rate Growth +1.1pp +0.4pp 21 of 54
Gross margin Profitability 79.2% 52.0% 2 of 45
Operating margin Profitability -134.6% -14.3% 44 of 52
Net margin Profitability -114.8% -12.2% 46 of 54
Free-cash-flow margin Cash generation -76.1% -1.3% 45 of 54
Stock pay as % of revenue Cash generation 16.0% 4.4% 44 of 53
Change in share count Balance sheet 1.0% 1.0% 22 of 46
Days sales outstanding Balance sheet 46 days 62 days 12 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Products $18.7M ▼ 11.4%
Assay and Other Service Revenue $2M —
Licenses $300,000 ▼ 98.2%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
United States $21.1M 63.8% ▼ 18.2%
Outside the US $11.9M 36.2% ▼ 7.1%

From Maxcyte, Inc.'s 10-K filed March 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$78.1M
Institutions reporting
123
Shares held vs prior quarter
▼ 3.2%
Positions opened / closed
27 / 33

Top buyers and sellers, Q2 2026: 78 institutions bought and 61 sold ; the biggest buyer was Jane Street Group, LLC (+1.5M shares) and the biggest seller Blackrock, Inc (−5.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Capricorn Fund Managers Ltd $10.1M 8.2M 12.9% 0.0%
Vitruvian Partners LLP $6.2M 5.0M 7.9% 0.0%
Vanguard Capital Management LLC $5M 4.0M 6.4% ▲ 1.2%
Morgan Stanley $4.5M 3.7M 5.8% ▲ 0.2%
Mudita Advisors LLP $4.1M 3.4M 5.3% 0.0%
Blackrock, Inc. $3.8M 3.1M 4.8% ▼ 65.2%
Brooklands Fund Management Ltd $3.7M 2.8M 4.7% ▲ 30.0%
BNP Paribas Asset Management Holding S.A. $3.4M 2.8M 4.4% 0.0%
Cadian Capital Management, LP $2.7M 2.2M 3.5% ▲ 27.8%
Peapod Lane Capital LLC $2.6M 2.1M 3.3% ▲ 59.6%
Renaissance Technologies LLC $2.4M 1.9M 3.0% ▼ 4.1%
AQR Capital Management LLC $2.3M 1.9M 3.0% ▲ 54.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Maxcyte, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $8,316 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $8,316 net selling
Insider Date Trade Shares Price Value
Swirsky Douglas J CHIEF FINANCIAL OFFICER March 17, 2026 Sell 10,142 $0.82 $8,316

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • October 14, 2026
  • August 12, 2026
  • May 12, 2026
  • March 24, 2026
  • January 12, 2026
  • November 12, 2025

Recent SEC filings

Data status

When each part of this page on Maxcyte, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Maxcyte, Inc. in brief

What does Maxcyte, Inc. do?
Maxcyte, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Maxcyte, Inc.'s stock ticker?
Maxcyte, Inc. trades under the ticker MXCT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Maxcyte, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Maxcyte, Inc. reported revenue of $31.1M, 13.2% lower than a year earlier, according to its SEC filings.
What is Maxcyte, Inc.'s free cash flow?
Maxcyte, Inc.'s free-cash-flow margin is -76.1% of revenue over the trailing twelve months, ranking 45 of the 54 life sciences tools & services companies we cover.
Who are Maxcyte, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Capricorn Fund Managers Ltd, Vitruvian Partners LLP and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Maxcyte, Inc.'s market cap?
On November 2, 2026, Maxcyte, Inc.'s market capitalisation was about $155M and net debt of -$15M. Market figures come from third-party market data and may be delayed.
Who are Maxcyte, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Maxcyte, Inc. are Bionano Genomics, Inc., Rapid Micro Biosystems, Inc., Omniab, Inc., Alpha Teknova, Inc. and Champions Oncology, Inc. The side-by-side comparison below sets their revenue, margins and growth against Maxcyte, Inc.'s.
Are insiders buying or selling Maxcyte, Inc. stock?
Over the last 12 months, Maxcyte, Inc.'s directors and officers reported 0 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Maxcyte, Inc.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Maxcyte, Inc. announces its own schedule.